Immuno Tace

  • What's involved: A Randomised phase II Clinical Trial of conditioning cyclophosphamide and Chemoembolisation with or without Vaccination with Dendritic Cells pulsed with HepG2 lysate ex vivo in Patients with Hepatocellular Carcinoma (Immuno tace)
  • Take part: Open
  • Principal Investigator: Dr Martin James
Research Theme | Gastrointestinal & Liver | Open Trials

A Randomised phase II Clinical Trial of conditioning cyclophosphamide and Chemoembolisation with or without Vaccination with Dendritic Cells pulsed with HepG2 lysate ex vivo in Patients with Hepatocellular Carcinoma (Immuno tace)

What's involved

A Randomised phase II Clinical Trial of conditioning cyclophosphamide and Chemoembolisation with or without Vaccination with Dendritic Cells pulsed with HepG2 lysate ex vivo in Patients with Hepatocellular Carcinoma (Immuno tace)

Principal Investigator

Dr Martin James

Take part

Open
Back to all trials

Contact Us

NIHR Biomedical Research Centre: Nottingham
Research & Innovation
D Floor (via South Block)
Nottingham University Hospitals NHS Trust
Queen’s Medical Centre
Derby Road
Nottingham
NG7 2UH

Telephone: 0115 924 9924

Director: Professor Ian Hall

Hosted by

Nottingham University Hospitals Logo

Nottingham University Hospitals Logo

We are a partnership between Nottingham University Hospitals NHS Trust and the University of Nottingham, supported by NHS and academic partners in Nottingham and across the East Midlands.

Website by Volute